Shares of Agios Pharmaceuticals (AGIO) rose more than 20% on May 28 after it entered into a deal with Royalty Pharma (RPRX) to sell the royalty rights on potential net sales of vorasidenib, a brain cancer therapy.Vorasidenib was a part of Agios’ oncology business that was sold to France-based pharmaceutical company Servier in 2021. Per the sale terms, the company is entitled to receive a 15% royalty on potential net sales of the drug in the United States following a possible FDA approval.Currently, the Serv ...

– Royalty Pharma to Acquire Rights to Agios' 15% Royalty on Potential Vorasidenib U.S. Net Sales for $905 Million Upfront upon FDA Approval of Vorasidenib; Agios to Share in Economics Above Certain Revenue Thresholds – – Agios Retains Rights to $200 Million Milestone Payment from Servier upon FDA Approval of Vorasidenib – – In Total, Agios to Receive $1.1 Billion in Payments upon FDA Approval of Vorasidenib; PDUFA Action Date of August 20, 2024 – CAMBRIDGE, Mass., May 28, 2024 (GLOBE NEWSWIRE) -- Agios Phar ...

Shares of Agios Pharmaceuticals (AGIO) have gained 3.2% over the past four weeks to close the last trading session at $32.69, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $41.33 indicates a potential upside of 26.4%.The mean estimate comprises six short-term price targets with a standard deviation of $8.12. While the lowest estimate of $30 indicates an 8.2% decline from the c ...

Agios Pharmaceuticals (AGIO) closed the last trading session at $32.80, gaining 10.4% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $41.33 indicates a 26% upside potential.The mean estimate comprises six short-term price targets with a standard deviation of $8.12. While the lowest estimate of $30 indicates an 8.5% decline from the current price level, the most optimistic analyst ...

CAMBRIDGE, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today announced that the company is scheduled to present at the BofA Securities 2024 Health Care Conference on Thursday, May 16, 2024, at 11:40 a.m. ET. A live webcast of the presentation can be accessed under "Events & Presentations" in the Investors section of the company's website at www.agios.com. A replay of the webcast w ...

Company Overview - Agios Pharmaceuticals is a leader in cellular metabolism and PK activation, focusing on therapies for rare diseases [2] - The company markets a first-in-class pyruvate kinase (PK) activator for adults with PK deficiency, which is the first disease-modifying therapy for this condition [2] - Agios is advancing a clinical pipeline that includes investigational medicines for alpha- and beta-thalassemia, sickle cell disease, pediatric PK deficiency, MDS-associated anemia, and phenylketonuria (PKU) [2] - Additionally, Agios is developing a preclinical TMPRSS6 siRNA as a potential treatment for polycythemia vera [2] Upcoming Events - Agios Pharmaceuticals is scheduled to present at the 2024 RBC Capital Markets Global Healthcare Conference on May 14, 2024, at 8:00 a.m. ET [1] - A live webcast of the presentation will be available on the company's website, with a replay archived for at least two weeks [1]

Q1 2024 Financial Results May 2, 2024 1 Agios conference call participants TOPIC PARTICIPANT Chris Taylor, VP Investor Relations and Corporate Introduction Communications Business Update Brian Goff, Chief Executive Officer Sarah Gheuens, M.D., Ph.D., ...

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Q1 2024 Earnings Conference Call May 2, 2024 8:00 AM ET Company Participants Chris Taylor - Vice President, Investor Relations and Corporate Communications Brian Goff - Chief Executive Officer Sarah Gheuens - Chief Medical Officer and Head, R&D Tsveta Milanova - Chief Commercial Officer Cecilia Jones - Chief Financial Officer Conference Call Participants Gregory Renza - RBC Capital Markets Divya Rao - TD Cowen Eric Schmidt - Cantor Alec Stranahan - Bank of America T ...

Company Performance - Agios Pharmaceuticals reported a quarterly loss of $1.45 per share, better than the Zacks Consensus Estimate of a loss of $1.64, and compared to a loss of $1.47 per share a year ago, indicating an earnings surprise of 11.59% [1] - The company posted revenues of $8.19 million for the quarter ended March 2024, missing the Zacks Consensus Estimate by 2.56%, and showing an increase from $5.61 million in the same quarter last year [1] - Over the last four quarters, Agios has surpassed consensus EPS estimates three times but has topped consensus revenue estimates only once [1] Stock Performance - Agios Pharmaceuticals shares have increased approximately 51.2% since the beginning of the year, significantly outperforming the S&P 500's gain of 5.2% [2] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$1.63 on revenues of $9.88 million, and for the current fiscal year, it is -$5.29 on revenues of $81.43 million [4] - The estimate revisions trend for Agios Pharmaceuticals is currently unfavorable, resulting in a Zacks Rank 4 (Sell), indicating expected underperformance in the near future [4] Industry Context - The Medical - Products industry, to which Agios belongs, is currently ranked in the bottom 41% of over 250 Zacks industries, suggesting potential challenges for stocks within this sector [5] - Another company in the same industry, biote Corp., is expected to report quarterly earnings of $0.05 per share, reflecting a year-over-year change of -94.7%, with revenues anticipated to be $47.09 million, up 5% from the previous year [5][6]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-36014 AGIOS PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 26-0662915 (State or Other Jurisdiction of In ...